Out of 11 patients with light chain disease, 9 had abnormal κ/λ ratios. It is unclear why half of the patients with MG by IFE had normal κ/λ ratios. Lower M-components in these patients ...
Zeripatamig is under clinical development by Light Chain Bioscience and currently in Phase I for Mantle Cell Lymphoma.